Ganitumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade

Introduction

Ganitumab Biosimilar, also known as Anti-IGF1R, CD221 mAb, is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF1R) and has shown promising results in preclinical studies. This biosimilar is a potential therapeutic option for various types of cancer, including breast, lung, and pancreatic cancer. In this article, we will discuss the structure, activity, and potential applications of Ganitumab Biosimilar as a research grade antibody.

Structure of Ganitumab Biosimilar

Ganitumab Biosimilar is a recombinant human IgG1 monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains consist of 446 amino acids, while the light chains consist of 214 amino acids. The antibody has a molecular weight of approximately 150 kDa. It is produced through recombinant DNA technology using Chinese hamster ovary (CHO) cells.

Activity of Ganitumab Biosimilar

Ganitumab Biosimilar specifically targets the IGF1R, a transmembrane receptor that is involved in cell growth, proliferation, and survival. The binding of Ganitumab Biosimilar to IGF1R prevents the activation of downstream signaling pathways, leading to inhibition of tumor growth and progression. This antibody has also been shown to induce antibody-dependent cellular cytotoxicity (ADCC), which further enhances its anti-tumor activity.

Applications of Ganitumab Biosimilar

Ganitumab Biosimilar has shown potential as a therapeutic option for various types of cancer. Preclinical studies have demonstrated its efficacy in breast, lung, and pancreatic cancer models. In breast cancer, Ganitumab Biosimilar has been shown to inhibit the growth of cancer cells and sensitize them to chemotherapy. In lung cancer, this antibody has been shown to inhibit tumor growth and metastasis. In pancreatic cancer, Ganitumab Biosimilar has been shown to reduce tumor growth and improve survival rates.

In addition to its potential as a therapeutic agent, Ganitumab Biosimilar can also be used as a research tool. It can be used to study the role of IGF1R in cancer development and progression. The antibody can also be used in diagnostic assays to detect the expression of IGF1R in cancer cells.

Advantages of Ganitumab Biosimilar

Compared to other IGF1R-targeting antibodies, Ganitumab Biosimilar has several advantages. It has a high binding affinity to IGF1R, which allows for effective inhibition of downstream signaling pathways. It also has a longer half-life, which means it can remain in the body for a longer period of time, providing sustained anti-tumor activity. Additionally, Ganitumab Biosimilar has a low immunogenicity profile, making it a safe and well-tolerated treatment option.

Conclusion

Ganitumab Biosimilar is a promising research grade antibody that specifically targets IGF1R and has shown potential as a therapeutic option for various types of cancer. Its unique structure and activity make it an effective inhibitor of tumor growth and progression. Further clinical studies are needed to fully evaluate its safety and efficacy in cancer treatment. However, Ganitumab Biosimilar holds great promise in improving outcomes for cancer patients and advancing our understanding of IGF1R signaling in cancer biology.